City Therapeutics, Inc. Stifel initiates coverage with buy rating; target price $34
CTY•Stifel initiated coverage of City Therapeutics, Inc. with a buy rating and a $34 target price.
Related News
TSMC board approves up to $500 million investment each in Anthropic and OpenAI
TSM•
Upstream Bio Q3 net loss widens 22% to $41.19 million
UPB•
Montauk Renewables files non-timely 10-Q with US SEC
MNTK•
Immunovant, Inc.: Truist Securities raises target price to $33 from $30
IMVT•
Zeta Global Holdings target price raised to $40 from $38
ZETA•